US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Acne Vulgaris · Plasmodium Falciparum Malaria · ATXI
AVENUE THERAPEUTICS
AVENUE THERAPEUTICS, INC.
AVENUE THERAPEUTICS drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Bay Harbor Islands, USA HQ
10 Employees
Public company Type
ATXI · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bay Harbor Islands, USA
- Employees
- 10
- Programs
- 4
- Drugs
- 8
- Patents
- 1
AVENUE THERAPEUTICS pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
AVENUE THERAPEUTICS drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist
-
Development asset linked to AVENUE THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.
- Target
- Ferriprotoporphyrin IX
- Mechanism
- Ferriprotoporphyrin IX inhibitor
-
Development asset linked to AVENUE THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Releases active oxygen.
- Mechanism
- Releases active oxygen
-
Development asset linked to AVENUE THERAPEUTICS in public FDA and regional records.
-
Development asset linked to AVENUE THERAPEUTICS in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist